Welcome to our dedicated page for Vyome Holdings SEC filings (Ticker: HIND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Vyome Holdings, Inc. (NASDAQ: HIND) filings with the U.S. Securities and Exchange Commission, along with AI-powered tools that help interpret the information. Vyome is a clinical-stage healthcare holding company focused on immuno-inflammatory conditions, AI-driven health applications, and AI-enabled medical devices, and its SEC filings offer structured detail on these activities.
Investors can review current reports on Form 8-K, where Vyome discloses material events such as its streamlined Nasdaq listing, financial results for reporting periods, and transactions like the acquisition of substantially all assets of Oculo, Inc. or the announcement of a binding letter of intent involving LiveChain, Inc. and Humanyze. These filings also confirm that Vyome’s common stock, par value $0.001 per share, is listed on The Nasdaq Capital Market under the symbol HIND and that the company qualifies as an emerging growth company.
The definitive proxy statement on Schedule 14A (DEF 14A) is another key document. It describes matters submitted to stockholders at the annual meeting, including the election of Class I directors, approval of the Vyome Holdings, Inc. 2025 Equity Incentive Plan, ratification of the independent registered public accounting firm, and advisory votes on executive compensation. The proxy statement also outlines governance structures and provides context on how the board oversees Vyome’s strategy.
Through this page, users can quickly locate Vyome’s quarterly and annual reports when available, as well as any future registration statements, proxies, or additional 8-Ks that discuss clinical progress for VT-1953 and other programs, capital structure details, or changes in governance. AI-generated summaries highlight the main points in lengthy documents, helping readers understand how specific items—such as equity plans, material transactions, or board decisions—relate to Vyome’s broader focus on immuno-inflammation, AI initiatives, and the US–India innovation corridor.
Vyome Holdings, Inc. furnished an investor presentation and a related product assessment report about VT-1953, its lead clinical candidate for treating symptoms of malignant fungating wounds. These materials are provided as Exhibit 99.1 under Regulation FD and are not deemed filed for liability purposes.
The company also reported that it issued a press release on January 27, 2026, summarizing key findings from an independent U.S. market assessment, commercial forecast, and valuation analysis for VT-1953, which is attached as Exhibit 99.2. Both exhibits are incorporated by reference and include forward-looking statements about business strategy, capital needs, market potential, and future operating results.
Vyome Holdings, Inc. filed a current report to announce that it released financial results for its third fiscal quarter ended September 30, 2025. On November 18, 2025, the company issued a press release describing these results, which is included as Exhibit 99.1 to this report.
The company notes that the press release and the related information are being furnished, not filed, under securities laws. This means the information carries different legal status and will only be incorporated into other filings if explicitly stated in those future documents.
Vyome Holdings, Inc. (HIND) reported a stock option grant to a director following its merger with Vyome Therapeutics, Inc. Under a previously signed Merger Agreement, Vyome Therapeutics became a subsidiary and the combined company was renamed Vyome Holdings, Inc.
The reporting person received 17,833 stock options to purchase Vyome Holdings common stock at an exercise price of $0.66 per share. Of these, 4,458 options were fully vested on the grant date, while the remaining 13,375 options are scheduled to vest in twelve equal monthly installments beginning on November 30, 2025, contingent on continued service. The grant was made under the company’s 2025 Equity Incentive Plan.
Vyome Holdings, Inc. (HIND)director of the company as of 08/15/2025, which is the date of the event requiring this statement. The form is filed by one reporting person and states in the explanation section that no securities are beneficially owned by the reporting person. This means the director reports holding no direct or indirect shares or derivative securities of Vyome Holdings at this time.
Vyome Holdings, Inc. director reports new share ownership following merger. A Form 4 discloses that Mohanjit Jolly, a director of Vyome Holdings (ticker HIND), acquired 454,456 shares of the company’s common stock on 08/15/2025. The shares were received in connection with a merger in which Raider Lifesciences Inc., a wholly owned subsidiary of Vyome Holdings, merged with Vyome Therapeutics, Inc., which became a subsidiary of Vyome Holdings.
Under the merger terms, each 5,000 shares of Vyome Therapeutics common or preferred stock were converted into 1 share of Vyome Holdings common stock. Jolly received the 454,456 Vyome Holdings shares in exchange for 2,272,280,000 shares of Vyome Therapeutics stock. The filing states these shares are held indirectly through Iron Pillar Fund I Ltd., where Jolly is a general partner and an advisor/representative for related investments.
Vyome Holdings, Inc. director reports no share ownership
A reporting person, identified as a director of Vyome Holdings, Inc. (HIND), filed a beneficial ownership report as of 08/15/2025. The filing states in the explanation section that no securities are beneficially owned, meaning the director reports holding no Vyome common stock or derivative securities for reporting purposes at that date. The report is filed as a single-person filing and is signed by /s/ Mohanjit Jolly on 11/18/2025, confirming this ownership status under the insider reporting rules.
Vyome Holdings, Inc. (HIND) reported a Form 4 insider transaction for a director relating to stock options granted in connection with its merger with Vyome Therapeutics, Inc. The filing shows a stock option (right to buy) covering 17,833 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, granted on 11/13/2025 and expiring on 07/30/2035. These options were issued under the company’s 2025 Equity Incentive Plan following the August 2025 merger in which Raider Lifesciences Inc., a wholly owned subsidiary, merged into Vyome Therapeutics, which now operates as a subsidiary of Vyome Holdings. Of the 17,833 options, 4,458 were fully vested on the grant date, while the remaining 13,375 vest in twelve equal monthly installments beginning on 11/30/2025, subject to continued service. After this transaction, the director beneficially owns 17,833 derivative securities directly.
Vyome Holdings, Inc. reported an equity award to a company director in connection with its merger with Vyome Therapeutics, Inc. Following the August 15, 2025 merger, outstanding Vyome Therapeutics stock options were assumed and converted into options over Vyome Holdings common stock.
Under this structure, the reporting person received options to purchase 624,432 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, granted on November 13, 2025. These options were fully vested on the grant date and were issued under the company’s 2025 Equity Incentive Plan. The filing reflects the director’s beneficial ownership of these derivative securities rather than an open-market share purchase or sale.
Vyome Holdings, Inc. (HIND) filed a Form 3 reporting that director Shiladitya Sengupta currently has no beneficial ownership of the company’s securities. This initial statement of beneficial ownership is triggered by an event dated 08/15/2025 and confirms that, as of that date, the director did not hold any non-derivative or derivative securities of Vyome Holdings.
Vyome Holdings, Inc. reported an option grant to its President and CEO, Venkat Nelabhotla, who also serves as a director. On 11/13/2025 he received stock options to purchase 615,149 shares of Vyome Holdings common stock at an exercise price of $0.66 per share, and these options were fully vested on the grant date under the company’s 2025 Equity Incentive Plan.
The filing also explains that, under a previously signed Merger Agreement, Raider Lifesciences Inc. merged into Vyome Therapeutics, Inc. on August 15, 2025, with Vyome Therapeutics becoming a subsidiary of the issuer. Following this transaction, the issuer was renamed Vyome Holdings, Inc., while Vyome Therapeutics continued as Vyome Therapeutics, Inc.
FAQ
What is the current stock price of Vyome Holdings (HIND)?
What is the market cap of Vyome Holdings (HIND)?
